Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orphan Drug Development: Could We Be Seeing The End Of P Values?

Executive Summary

Panel of experts stresses need to move toward innovative approaches for rare disease drug development such as Bayesian methods, but this would require a paradigm shift in US FDA's regulatory structure. 
Advertisement

Related Content

Woodcock Hopes I-SPY 2 Trial Is 'Blazing The Trail' For Future Adaptive Design Uptake
Orphan Drug Policy Changes To Be Considered Under US FDA's FY 2019 Budget Proposal
Moscicki's Move From FDA To PhRMA About 'Best' Use Of Leadership Skills
Clinical Trial System 'Broken,' But Modernization Long Way Away – Woodcock
Master Protocols Are Both Welcome And Inevitable – US FDA's Woodcock
FDA Encourages Pediatric Master Protocols With Bayesian Approach

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS122746

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel